Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer’s master regulator DOI Creative Commons
Shiyu Liu, Dan Liu, Y Yuan

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13

Published: April 29, 2025

MYC, a master regulator in oncogenesis, has long been deemed "undruggable" due to its intrinsically disordered structure. However, recent advances are overturning this view, with direct inhibitors like Omomyc (OMO-103) and PROTAC-based degraders such as WBC100 showing promising clinical progress. Complementary strategies-including BET CDK9 inhibitors, RNA-based therapeutics, nanobodies, engineered proteases-are expanding the therapeutic landscape. Despite challenges specificity, toxicity, delivery, these innovations underscore MYC's emerging druggability. Moreover, combination therapies integrating MYC chemotherapy, radiotherapy, or immunotherapy demonstrate synergistic potential. This article advocates for multi-dimensional, biomarker-guided approach targeting, emphasizing rational drug combinations continued innovation overcome resistance improve outcomes MYC-driven cancers.

Language: Английский

A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer DOI Creative Commons

Amir Mahdi Khamaneh,

Davoud Jafari-Gharabaghlou, Khalil Ansarin

et al.

Oncology Reviews, Journal Year: 2025, Volume and Issue: 19

Published: Feb. 12, 2025

Breast cancer is the most prevalent neoplasm in women. ER + (Luminal subtype), representing over 70% of breast tumors, a genetically diverse group. Structural and Numerical-Chromosomal instability initiates tumor development recognized as primary driver genetic alteration luminal tumors. Genomic refers to increased tendency cells accumulate genomic alterations during cell proliferation. The cycle check-point response constant stable drives this process. impact CNV patterns aneuploidies proliferation perturbation has recently been highlighted by scientists Luminal chromosomal on therapy prognosis not new concept. Still, degree emerging leads following deregulation could be predicted CNVs-based reclassification In review, we try explain effect CIN that ended with altered decision-making for strategy patients cancer.

Language: Английский

Citations

0
Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer’s master regulator DOI Creative Commons
Shiyu Liu, Dan Liu, Y Yuan

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13

Published: April 29, 2025

MYC, a master regulator in oncogenesis, has long been deemed "undruggable" due to its intrinsically disordered structure. However, recent advances are overturning this view, with direct inhibitors like Omomyc (OMO-103) and PROTAC-based degraders such as WBC100 showing promising clinical progress. Complementary strategies-including BET CDK9 inhibitors, RNA-based therapeutics, nanobodies, engineered proteases-are expanding the therapeutic landscape. Despite challenges specificity, toxicity, delivery, these innovations underscore MYC's emerging druggability. Moreover, combination therapies integrating MYC chemotherapy, radiotherapy, or immunotherapy demonstrate synergistic potential. This article advocates for multi-dimensional, biomarker-guided approach targeting, emphasizing rational drug combinations continued innovation overcome resistance improve outcomes MYC-driven cancers.

Language: Английский

Citations

0